Massaro Fulvio, Andreozzi Fabio, Abrassart Tom, Castiaux Julie, Massa Hanne, Rizzo Ornella, Vercruyssen Marie
Hematology Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.
Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective.
在过去三十年中，淋巴增生性疾病的治疗发生了深刻变化，这主要归功于越来越多的创新疗法，这些疗法有可能重新定义临床管理模式。一个主要影响与单克隆抗体、检查点抑制剂、双特异性抗体和嵌合抗原受体T（CAR-T）细胞疗法的发展有关。本综述讨论了针对各种血液系统恶性肿瘤的临床试验现状，强调了有前景的早期结果以及克服耐药性的策略。淋巴增生性疾病包括一系列病症：在霍奇金淋巴瘤（HL）中，目标是通过将免疫疗法纳入一线治疗来降低化疗相关毒性，而外周T细胞淋巴瘤（PTCL）则缺乏有效的靶向治疗方法。该综述强调了治疗格局正朝着精准医学以及毒性更低但更有效的治疗方式转变。
